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At present dengue is the most rapidly spreading arthropod-borne viral disease of human beings with significant morbidity and mortality. Dengue viral infection is mostly 
asymptomatic, but in some, it produces a wide spectrum of clinical 
manifestations. All the four virus serotypes were found producing 
epidemics in India [1]. Coagulopathy associated with dengue 
fever is well observed, but unfortunately, underlying mechanisms 
still remain unclear. Thrombocytopenia is unlikely to produce 
spontaneous bleeding in dengue. Thrombocytopenia associated 
with coagulopathy increases the severity of hemorrhage.
The listed causes of bleeding in dengue hemorrhagic fever 
(DHF) are abnormal coagulation profile, thrombocytopenia, 
platelet dysfunction, prothrombin complex deficiency secondary 
to liver involvement, endothelial injury, prolonged aPTT and 
disseminated intravascular coagulation (decrease in fibrinogen 
level, increased level of fibrinogen degradation product, increased 
level of D-Dimer, consumptive coagulopathy, activation of 
mononuclear phagocytes), sequestration of platelets, acidosis, 
hemorrhagic gastritis, and ulceration. Bleeding may present as 
spontaneous bleeding in skin, black tarry stool, epistaxis, gum 
bleed, hematuria, hematemesis, intracranial bleed, and increase 
in menstrual flow. Packed cell transfusion/fresh frozen plasma 
(FFP) along with platelets may be required in cases of severe 
bleeding with coagulopathy. In some patients, the aspartate 
aminotransferase/alanine aminotransferase level may be very high 
and prothrombin time (PT) may be prolonged. If PT is prolonged 
intravenous vitamin K1 may be initiated in such conditions [1]. 
In bleeding if HCT is low or not rising, blood transfusion and 
vitamin K1 intravenously should be considered [2].
Vitamin K is an essential cofactor for a microsomal enzyme 
that catalyzes the post-translational carboxylation of multiple, 
specific, peptide-bound glutamic acid residues in inactive 
hepatic precursors of factors II, VII, IX, and X [3]. If the PT 
is prolonged by 4-6 seconds or more (international normalized 
ratio [INR] ≥1.5), and there is any evidence of altered sensorium 
or INR >2 without encephalopathy, the diagnosis of acute liver 
failure (ALF) is established. Vitamin K (5-10 mg subcutaneously) 
should be administered routinely at least once since vitamin K 
deficiency has been reported in patients with ALF [4,5]. The 
most common site of bleeding in ALF is from superficial gastric 
erosions. To a lesser extent bleeding also presents spontaneously 
from nasopharyngeal, pulmonary, and genitourinary sources [6].
Pharmacodynamic activity of vitamin K is seen in its deficient 
state only. Its intravenous administration controls hemorrhage 
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within 3-6 h. A normal prothrombin level may often be obtained 
in 12-14 h. Repeated large doses of vitamin K are not warranted 
if the initial response is unsatisfactory. Although a 30-day supply 
of vitamin K is stored in the normal liver, acutely ill patients can 
become vitamin K-deficient within 7-10 days [7]. There is no 
known toxicity associated with large doses of vitamin K1 [8]. PT is 
an insensitive marker of vitamin K deficiency. Prothrombin must 
decrease to approximately 50% of normal levels before a change 
in PT status is noted. Proteins induced by vitamin K absence for 
factor II (PIVKA-II), a highly sensitive and specific marker is 
increasingly being used to assess vitamin K status. PIVKA-II 
values >3 ng/mL are indicative of vitamin K deficiency.
There is a paucity of evidence regarding the efficacy of 
vitamin K in DHF. Search using words dengue, and vitamin K 
in PubMed, Cochrane, Index Copernicus, Embase, Lilacs yielded 
no relevant results. Although WHO included vitamin K in the 
necessary drugs list for dengue management in its guidelines, 
routine administration of vitamin K in DHF was not advocated [9]. 
Vitamin K is advised in hepatic failure and hepatic encephalopathy 
associated with dengue in few guidelines. Recombinant Factor 
VIIa has been tried and advocated at some centers [10,11]. 
However, it is prudent to study the utility of vitamin K in DHF 
before going for such costly and short-lived therapies. Therefore, 
we planned this study with an objective to assess the clinical 
efficacy of vitamin K to control bleeding in children with DHF.
METHODS
It is a retrospective study conducted at the Institute of Child 
Health, Niloufer Hospital, Hyderabad, from June to November 
of 2015. Medical records of children from 1 month to 15 years 
of age admitted with confirmed and clinical DHF were 
reviewed. Only children having clinical features of dengue with 
documentation of the status of bleeding before and after the 
intravenous vitamin K administration were included in the study. 
Evaluation of the history, physical examination findings and/or 
full blood count and hematocrit was done. According to the WHO 
guidelines, patients admitted with clinical features of dengue with 
negative serological evidence were included in the clinical DHF 
group. Patients with serological evidence of dengue (positive NS1 
antigen and/or anti-dengue IgM, and/or anti-dengue IgG) along 
with clinical features of DHF were included in the confirmed 
group.
Patients underwent NS 1 Ag testing with RDT kits at the time of 
admission while IgM and IgG testing for dengue was done by Alere 
SD BIOLINE Dengue IgG/IgM rapid immunochromatographic 
test after 5 days of fever. Records without clinical evidence of 
dengue, with clinical and laboratory evidence of other causes 
of bleeding, without serial documentation of bleeding, and with 
no vitamin K administration were excluded from the study. It is 
emphasized above that thrombocytopenia alone is not likely to 
cause bleeding in dengue, and the previous studies mentioned by 
WHO showed that correction of platelet count with transfusion 
failed to prevent bleeding. Thus, thrombocytopenia cannot be 
considered as an independent factor. Hence, cases with bleeding 
and thrombocytopenia due to dengue were also included in 
the study. Those who had bleeding and were not tested for PT, 
were also included if they had other evidence of dengue and no 
evidence of other cause of bleeding. Clinical and laboratory data 
from the DHF case records were subjected to statistical analysis 
with SPSS software.
Based on the pharmacokinetics of vitamin K, cessation 
of bleeding within 24 h of vitamin K administration without 
recurrence was taken as clinical evidence of efficacy of vitamin K. 
Cessation of bleeding as a clinical benefit due to treatment is 
clinically relevant, sensitive (responsive to change) and is both 
recognized and used by physicians. Temporal correlation of 
response to blood products was assessed and wherever vitamin K 
was independently clinically effective, it was taken as response.
RESULTS
About 26 of the 100 patients with confirmed DHF and 27 of the 
133 clinical DHF met the inclusion criteria. In confirmed group, 
10 were male, 16 were female, and in clinical group 17 were 
male, 10 were female. The details of the patients are presented 
in Table 1.
The presentation of bleeding in the decreasing order of 
frequency was malena, epistaxis, hematuria, hematemesis, gum 
bleed, ecchymoses, and hematochezia. 11 children (20.7%) had 
bleeding from more than one site. Deranged PT-INR (≥1.3) was 
seen in 96.9% of tested patients (31 of 32 tested) and one child 
had an INR of 1.28. Hepatomegaly was seen in 77% total patients. 
Patients were not tested for coagulation after improvement. This 
makes it difficult to compare parameters from admission to 
improvement. Thrombocytopenia was seen in 80% of the total 
patients.
Confirmed DHF patients (n=74) who were not included in 
the group had a mean hospital admission duration of 4.46±2.15 
(Range - 0.5-9 days). Clinical DHF patients (n=106) who were 
not included in the group had a mean hospital admission duration 
of 4.53±3.2, (Range - 0.25-27 days). Both these groups had lesser 
admission duration than the study groups because of patients in 
the study groups had to stay long due to more significant bleeding. 
As there are no guidelines yet to give routine vitamin K to DHF, 
only patients with significant bleeding received vitamin K.
Clinical response to vitamin K was observed in 80.8% 
of confirmed (95% confidence interval [CI] with continuity 
correction: 60-92.7%) and 92.6% of clinical DHF (95% CI with 
continuity correction: 74.2-98.7%).
DISCUSSION
In the study group, presentations of bleeding suggest 
coagulation failure as the main contributor to bleeding than the 
thrombocytopenia. Elevated PT suggests that liver dysfunction is 
the major contributor to bleeding. At our institute, FFP could not 
be given 6 hourly or as an infusion and bleeding continued in 
spite of 1 or 2 infusions of FFP. Two such children responded 
to vitamin K. As thrombocytopenia was not the main cause of 
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can be answered in a large, well-designed randomized controlled 
trials. 5 of 7 children who failed to respond to vitamin K, received 
further transfusions. Of the remaining two children who did not 
respond to vitamin K, one recovered with spontaneous recovery 
of platelet count, and another one was taken away against medical 
advice by parents. Overall response rate to vitamin K was 86.8% 
(95% CI: 74-94%).
A large body of clinical and experimental evidence points 
to the involvement of the liver in the pathobiology of dengue 
virus infections of humans. The balance of evidence suggests 
that hepatocytes are directly involved as the sites of dengue 
replication, adding to the total viral burden [12]. In ALF, about 
25% can have subclinical vitamin K deficiency, which can 
be corrected by intravenous vitamin K. In clinical practice, 
a decrease in PT by 30% following intravenous vitamin K 
confirms vitamin K deficiency [13]. Failure to observe an 
increase in circulating levels of the vitamin K-dependent factor 
VII by 25% after intravenous vitamin K suggests inadequate 
hepatic synthetic reserve [14]. Response to vitamin K was less in 
the confirmed group, owing to more severe involvement of liver 
than the clinical group. Routine use of vitamin K in DHF may 
control bleeding if liver dysfunction is not very severe. Early 
institution of vitamin K in DHF may prevent anemia, and reduce 
the need for transfusions.
High prevalence of anemia in children of developing 
countries is further burdened by recurrent epidemics of DHF. 
With this in mind, it may be justified to give at least one dose 
of vitamin K to all children with DHF at the earliest notice of 
bleeding as there is no evidence of toxic effects due to vitamin 
K in children. This response to vitamin K can be observed 
prospectively by the clinicians while managing DHF. Since the 
response to vitamin K, if present is not short-lived as in other 
therapies like FFP, rFVIIa, vitamin K may be considered as the 
initial priority over these.
If very little is known about a subject, sequence of research 
designs will efficiently build up reliable information. As cause-
effect conclusions in retrospective and observational studies are 
difficult to arrive at, randomized controlled studies are necessary 
using serial monitoring of bleeding, vitamin K by high pressure 
liquid chromatography, PIVKA II estimation, Factor VII, and PT 
before and after vitamin K administration in children with DHF, 
which can serve as definite evidence.
CONCLUSIONS
As can be seen, vitamin K is clinically effective in controlling 
bleeding in DHF. Routine administration of vitamin K to 
children with DHF at the earliest may reduce the need for 
blood transfusions and the burden of anemia. For cause-effect 
conclusion well designed randomized controlled trials using 
vitamin K administration in DHF, measurement of response 
to vitamin K with factor VII levels, and serial monitoring of 
bleeding, coagulation profile, and estimation of vitamin K, and 
PIVKA II levels are needed.
Table 1: Observations in children with DHF who received 
vitamin K
Observation Confirmed 
DHF (n=26)
Clinical 
DHF ( n=27)
n (%) or  
positive/tested
n (%) or  
positive/tested
Fever
Mean±SD
26
5.35±1.81
26
4.35±3.17
Vomiting 18 (69.2) 14 (51.8)
Malena 18 (69.2) 16 (59.2)
Epistaxis 8 (30.8) 5 (18.5)
Hematuria 3 (11.5) 4 (14.8)
Gum bleed 1 (3.8) 0
Ecchymoses 0 1 (3.7)
Hematemesis 0 2 (7.4)
Red stools 0 1 (3.7)
Petechiae 1 (3.8) 1 (3.7)
>1 site of bleeding 8 (30.8) 3 (11.1)
Jaundice 1 (3.8) 1 (3.7)
Hepatomegaly 24 (92.3) 17 (62.9)
Liver tenderness 18 (69.2) 10 (37)
Hypotension 21 (80.8) 17 (63)
Thrombocytopenia 24 (92.3) 18 (66.6)
High PCV 6 (23) 9 (33.3)
Leucopenia 5 (19.2) 4 (14.8)
Hyperbilirubinemia 2/6 1/7
Elevated AST 1/2
Elevated ALT (range) 4/4 (129-2790) 2/3 (233-479)
Elevated PT (INR≥1.3) 14/14 17/18
PT-INR 1.3-2 6 11
PT-INR 2-5 4 3
PT-INR>5 4 3
Hospital stay (days)
Mean±SD 5.61±2.04 5.31±2.63
Range 3-12 2-11
FFP received 4 (15.4) 1 (3.7)
Platelet transfusion 8 (30.8) 3 (11.1)
PRBC received 2 (7.7) 0
Anemia with CCF 1 (3.8) 0
Vitamin K received 26 27
Response to vitamin K 21 (80.8) 25 (92.6)
FFP: Fresh frozen plasma, DHF: Dengue hemorrhagic fever, PCV: Packed cell 
volume, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, 
PT: Prothrombin time, INR: International normalized ratio, SD: Standard deviation, 
PRBC: Packed red blood cells, CCF: Congestive cardiac failure
bleeding, 7 children who continued to bleed in spite of platelet 
transfusion responded to vitamin K. One child who needed PRBC 
for anemia due to prolonged bleeding stopped to bleed after 
vitamin K. Clinical course of the above mentioned 10 patients 
(18.9%), demonstrates the role of vitamin K in the cessation 
of bleeding as more likely than the spontaneous recovery from 
dengue illness. In the rest 36 patients who had cessation of 
bleeding after vitamin K, the possibility of spontaneous recovery 
as the cause of cessation of bleeding is difficult to exclude, and this 
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